Cwm LLC Sells 5,703 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Cwm LLC lessened its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 5.2% in the fourth quarter, HoldingsChannel reports. The fund owned 103,014 shares of the biotechnology company’s stock after selling 5,703 shares during the period. Cwm LLC’s holdings in Arrowhead Pharmaceuticals were worth $3,152,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the company. Fifth Third Bancorp raised its position in shares of Arrowhead Pharmaceuticals by 112.0% in the third quarter. Fifth Third Bancorp now owns 988 shares of the biotechnology company’s stock valued at $27,000 after buying an additional 522 shares in the last quarter. Washington Trust Advisors Inc. acquired a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter valued at approximately $25,000. New York State Common Retirement Fund raised its position in shares of Arrowhead Pharmaceuticals by 2.4% in the third quarter. New York State Common Retirement Fund now owns 42,866 shares of the biotechnology company’s stock valued at $1,152,000 after buying an additional 999 shares in the last quarter. Teacher Retirement System of Texas raised its position in shares of Arrowhead Pharmaceuticals by 3.7% in the third quarter. Teacher Retirement System of Texas now owns 28,950 shares of the biotechnology company’s stock valued at $778,000 after buying an additional 1,041 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. raised its position in Arrowhead Pharmaceuticals by 96.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 2,753 shares of the biotechnology company’s stock valued at $74,000 after purchasing an additional 1,352 shares in the last quarter. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Stock Down 2.1 %

Shares of ARWR opened at $23.29 on Thursday. The firm’s fifty day simple moving average is $28.40 and its two-hundred day simple moving average is $28.92. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $20.67 and a 12 month high of $42.48.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings results on Tuesday, February 6th. The biotechnology company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.46). The firm had revenue of $3.55 million for the quarter, compared to the consensus estimate of $35.60 million. Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 90.77%. The business’s revenue was down 94.3% compared to the same quarter last year. During the same period last year, the company posted ($0.39) EPS. On average, equities research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.7 earnings per share for the current year.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 57,499 shares of the company’s stock in a transaction dated Wednesday, January 31st. The shares were sold at an average price of $32.35, for a total transaction of $1,860,092.65. Following the transaction, the chief executive officer now owns 3,715,048 shares in the company, valued at $120,181,802.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Arrowhead Pharmaceuticals news, Director Hongbo Lu bought 1,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were bought at an average price of $27.49 per share, for a total transaction of $27,490.00. Following the acquisition, the director now directly owns 31,680 shares of the company’s stock, valued at approximately $870,883.20. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 57,499 shares of the company’s stock in a transaction dated Wednesday, January 31st. The stock was sold at an average price of $32.35, for a total transaction of $1,860,092.65. Following the completion of the sale, the chief executive officer now owns 3,715,048 shares in the company, valued at approximately $120,181,802.80. The disclosure for this sale can be found here. Company insiders own 4.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ARWR. Bank of America boosted their price objective on shares of Arrowhead Pharmaceuticals from $29.00 to $37.00 and gave the company a “buy” rating in a research report on Tuesday, January 2nd. Citigroup boosted their target price on shares of Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 7th. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $34.00 to $36.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 7th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $50.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $90.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $53.45.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.